Editas Medicine (EDIT) Stock Forecast, Price & News

Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

Is Editas Medicine a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Editas Medicine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View analyst ratings for Editas Medicine or view top-rated stocks.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Editas Medicine.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) announced its quarterly earnings data on Wednesday, May, 4th. The company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($0.81) by $0.07. The firm had revenue of $6.80 million for the quarter, compared to the consensus estimate of $3.85 million. Editas Medicine had a negative trailing twelve-month return on equity of 32.88% and a negative net margin of 721.60%. The company's quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.86) earnings per share.
View Editas Medicine's earnings history.

What price target have analysts set for EDIT?

8 equities research analysts have issued 12 month price objectives for Editas Medicine's stock. Their forecasts range from $15.00 to $80.00. On average, they anticipate Editas Medicine's stock price to reach $36.00 in the next year. This suggests a possible upside of 226.7% from the stock's current price.
View analysts' price targets for Editas Medicine or view top-rated stocks among Wall Street analysts.

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the following people:

• Mr. James C. Mullen, Chairman, Pres & CEO (Age 63, Pay $1.01M) (LinkedIn Profile)
• Ms. Michelle Robertson, Exec. VP, CFO, Principal Accounting Officer, Treasurer & Assistant Sec. (Age 55, Pay $641.74k)
• Dr. Mark S. Shearman, Exec. VP & Chief Scientific Officer (Age 62, Pay $639.89k)
• Dr. Bruce E. Eaton Ph.D., Exec. VP & Chief Bus. Officer (Age 68, Pay $1.09M)
• Dr. Feng Zhang Ph.D., Co-Founder & Scientific Advisory Board Member
• Dr. George McDonald Church Ph.D., Co-Founder & Scientific Advisory Board Member (Age 68)
• Dr. J. Keith Joung M.D., Ph.D., Co-Founder & Scientific Advisory Board Member
• Dr. David R. Liu Ph.D., Co-Founder & Scientific Advisory Board Member
• Mr. Harry R. Gill III, Sr. VP of Operations (Age 61)
• Ron Moldaver, Investor Relations

Who are some of Editas Medicine's key competitors?

Some companies that are related to Editas Medicine include Iovance Biotherapeutics (IOVA), Beam Therapeutics (BEAM), Bavarian Nordic A/S (BVNRY), Fate Therapeutics (FATE), Twist Bioscience (TWST), Relay Therapeutics (RLAY), SpringWorks Therapeutics (SWTX), BioCryst Pharmaceuticals (BCRX), ImmunityBio (IBRX), Vaxcyte (PCVX), Krystal Biotech (KRYS), Immunocore (IMCR), Exscientia (EXAI), Valneva (VALN) and Vericel (VCEL).
View all of EDIT's competitors.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.02%), BlackRock Inc. (9.14%), State Street Corp (7.98%), JPMorgan Chase & Co. (1.83%), Sumitomo Mitsui Trust Holdings Inc. (1.51%) and Nikko Asset Management Americas Inc. (1.51%). Company insiders that own Editas Medicine stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels and Michelle Robertson.
View institutional ownership trends for Editas Medicine.

Which major investors are selling Editas Medicine stock?

EDIT stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Goldman Sachs Group Inc., JPMorgan Chase & Co., Jane Street Group LLC, Simplex Trading LLC, and Citigroup Inc.. Company insiders that have sold Editas Medicine company stock in the last year include Bruce Eaton, James C Mullen, Lisa Anne Michaels, and Michelle Robertson.
View insider buying and selling activity for Editas Medicine or view top insider-selling stocks.

Which major investors are buying Editas Medicine stock?

EDIT stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Renaissance Technologies LLC, CQS US LLC, Assenagon Asset Management S.A., Vanguard Group Inc., Connor Clark & Lunn Investment Management Ltd., and UBS Group AG.
View insider buying and selling activity for Editas Medicine or or view top insider-buying stocks.

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $11.02.

How much money does Editas Medicine make?

Editas Medicine has a market capitalization of $756.41 million and generates $25.54 million in revenue each year. The company earns $-192.50 million in net income (profit) each year or ($2.730010) on an earnings per share basis.

How many employees does Editas Medicine have?

Editas Medicine employs 264 workers across the globe.

What is Editas Medicine's official website?

The official website for Editas Medicine is www.editasmedicine.com.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at (617) 401-9000 or via email at [email protected].